Medibiofarma has just closed a financing round of 1.2 million euros, supported by the founder’s and other VC partners with proven experience in the field of health and technology, such as Sodena...
To make disease-modifying first-in-class immuno-oncology treatments available to patients suffering from devastating conditions such as cancer
How do we achieve our vision
Medibiofarma focused internal resources on areas where lies the experience of the management team:
- Virtual drug design
- Medicinal Chemistry
- In Vitro Pharmacology
- Intellectual Property
The remaining activities needed for the full compound characterization and the nomination of a development candidate, such as in vivo pharmacology and toxicology and IND-enabling studies are carried out through partnerships with several companies (CROs), Research Centers and Universities.